Impact of diabetes on clinical outcomes after revascularization with sirolimus-eluting and biolimus-eluting stents with biodegradable polymer from the SORT OUT VII trial

Julia Ellert, Evald Høj Christiansen, Michael Maeng, Bent Raungaard, Svend Eggert Jensen, Steen Dalby Kristensen, Karsten Tange Veien, Anders Bo Junker, Lars Jakobsen, Jens Aarøe, Christian Juhl Terkelsen, Johnny Kahlert, Anton Boel Villadsen, Hans Erik Bøtker, Lisette Okkels Jensen

Research output: Contribution to journalJournal articleResearchpeer-review

12 Citations (Scopus)
56 Downloads (Pure)

Abstract

OBJECTIVES: In this substudy of the SORT OUT VII trial, the clinical outcomes among patient with diabetes mellitus treated with Orsiro sirolimus-eluting stent (O-SES; Biotronik, Bülach, Switzerland) or Nobori biolimus-eluting stent (N-BES; Terumo, Tokyo, Japan) were compared.

BACKGROUND: Diabetes is associated with increased risk of target lesion failure (TLF) after percutaneous coronary intervention.

METHODS: In total, 2525 patients were randomized to stent implantation with O-SES (n = 1261, diabetes: n = 236) or N-BES (n = 1264, diabetes: n = 235). The primary endpoint, TLF, was a composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 2 years.

RESULTS: At 2 year, TLF did not differ between O-SES vs N-BES in diabetic (9.3% vs 9.4%; RR 0.98, 95% CI 0.54-1.78) patients. The individual components of the primary endpoint did not differ among stent type. In diabetics, cardiac death occurred in 3% of O-SES-treated and in 3.8% of N-BES-treated patients (RR 0.77, 95% CI 0.29-2.08), MI occurred in 3.0% of O-SES-treated and in 3.8% of N-BES-treated patients (RR 0.76, 95% CI 0.28-2.06) and TLR occurred in 5,5% of O-SES-treated and in 6.0% of N-BES-treated patients (RR 0.91, 95% CI 0.43-1.95).

CONCLUSION: TLF did not differ between O-SES- and N-BES-treated diabetic patients.

Original languageEnglish
JournalCatheterization and Cardiovascular Interventions
Volume93
Issue number4
Pages (from-to)567-573
Number of pages7
ISSN1522-1946
DOIs
Publication statusPublished - 1 Mar 2019

Keywords

  • Nobori stent
  • Orsiro stent
  • drug-eluting stent
  • target lesion failure

Fingerprint

Dive into the research topics of 'Impact of diabetes on clinical outcomes after revascularization with sirolimus-eluting and biolimus-eluting stents with biodegradable polymer from the SORT OUT VII trial'. Together they form a unique fingerprint.

Cite this